HER2-Targeted Therapy in Upper GI Cancer
Sam Klempner, MD, provides insight on HER2-targeted therapy for patients with upper GI cancer, and the Oncology Brothers recap the entire discussion.
The Role for Comprehensive NGS Testing in Upper GI Cancers
Medical oncologists discuss the role for comprehensive next-generation sequencing (NGS) in upper GI cancers and the potential role for zolbetuximab.
Treatment Paradigm for Metastatic Upper GI Cancers
Dr Klempner and the Oncology Brothers discuss the treatment paradigm for patients with metastatic upper GI cancers.
Treating Residual Disease in Upper GI Cancers Following FLOT Treatment
The Oncology Brothers and Sam Klempner, MD, offer comprehensive insights on treating residual disease in upper GI cancers following FLOT treatment.
Upper GI Malignancies: Treatment Paradigm for T2 Disease and Beyond
Sam Klempner, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment strategies for esophageal, GE junction, and gastric cancers.
Sam Klempner, MD, Looks at Broad Use of ctDNA in Oncology
Sam Klempner, MD, spoke about how clinicians exploring use of ctDNA in gastrointestinal cancers may inform their research with results from other tumor types.
Sam Klempner, MD, Talks ctDNA for Nonmetastatic Gastric and Esophageal Cancers
Sam Klempner, MD, spoke about clinical management and ctDNA for gastrointestinal cancers.
Sam Klempner, MD, Discusses Minimal Residual Disease in Gastrointestinal Cancers
Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.
Sam Klempner, MD, Reviews ctDNA Role in Gastroesophageal Cancers
Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.
